OM1 expands real-world evidence in respiratory and ENT with new asthma and chronic rhinosinusitis real-world datasets

5 Oct 2023

Written by Linda Essex

Artificial intelligence and machine learning Health data News Real-world evidence

OM1 launches asthma and chronic rhinosinusitis real-world datasets to expand real-world evidence in respiratory and ENT.

OM1, a real-world data (RWD) technology company with a focus on chronic diseases, has announced the launch of two new real-world clinical datasets in chronic rhinosinusitis (CRS) and asthma. This expansion of its respiratory and ENT RWD network has the potential to deliver real-world evidence (RWE) insights in asthma and CRS into patient subtypes, treatment effectiveness and patient outcomes, for accelerating research and improving decision-making.

Millions of Americans are impacted by respiratory diseases and the number continues to rise as air quality declines. It is estimated that 25 million people in the US are diagnosed with asthma, and 5–12% of the global population is affected by CRS.

OM1’s respiratory and ENT network of research-grade RWD has been developed through an exclusive partnership with the American Academy of Otolaryngology and Head and Neck Surgery Foundation. This collaboration provides access to rich data from thousands of clinicians and more than 25 million patient visits across all 50 US states, including patient reported outcomes, social determinants of health, and patient subtypes and classification data.

“Having access to deep clinical information on clinical presentation, treatments, and outcomes opens a world of incredible opportunity to improve care at both the population and individual patient level,” commented Richard Gliklich, CEO of OM1.

The new asthma and CRS datasets are each derived from longitudinal follow-up of approximately 500,000 individuals seen by US specialists and will continue to grow. The constituent RWD focus on patient characteristics, symptoms, treatments, clinical outcomes and healthcare resource utilization.

This announcement of OM1’s expansion of its respiratory and ENT RWD network follows hot on the heels of additions to both its dermatology RWD network and mental health and neuroscience RWD network in September 2023.